Filed Pursuant to Rule 424(b)(3)

Registration No. 333-257905

 

PROSPECTUS

 

 

ONCOCYTE CORPORATION

 

9,436,465 SHARES OF COMMON STOCK

 

This prospectus relates to the potential resale from time to time of up to 9,436,465 shares (“Resale Shares”) of common stock of Oncocyte Corporation (“Company” or “Oncocyte”) by the selling shareholders named in this prospectus. The Resale Shares consist of (i) 1,630,229 shares of Oncocyte common stock beneficially owned by certain selling shareholders; (ii) 7,213,089 shares (“Earnout Shares”) of Oncocyte common stock that may become issuable to certain selling shareholders as earnout payments pursuant to the terms of a Merger Agreement (as defined herein) described in this prospectus, contingent upon the achievement of milestones specified in the Merger Agreement and whether Oncocyte elects to pay all or a portion of the earnout payments to certain selling shareholders in shares of Oncocyte common stock; and (iii) 593,147 shares (“Restructured Shares”) of Oncocyte common stock that may become issuable to certain named selling shareholders as payments for restructured liabilities incurred by Chronix Biomedical, Inc. pursuant to the terms of agreements between Oncocyte and such selling shareholders contingent upon whether Oncocyte elects to pay all of a portion of the payments to the selling shareholder in shares of its common stock. We calculated the number of Earnout Shares based on the assumption that the maximum number of shares of our common stock that remains available for issuance pursuant to the Merger Agreement may be issued as earnout payments. The actual number of Earnout Shares issued to those selling shareholders as earnout payments, if any, could be materially less than 7,213,089 shares of common stock depending on (a) whether and to what extent the applicable future milestones are achieved, (b) the amount of offsets for certain liabilities of Chronix Biomedical, Inc., (c) whether we elect to pay all or a portion of the earnout payments to those selling shareholders in shares of our common stock, and (d) the actual closing price of our common stock on the trading day immediately preceding the date upon which we publicly announce that a milestone has been satisfied. Likewise, the actual number of Restructured Shares issued to the selling shareholders as payments for restructured liabilities, if any, could be materially less than 593,147 shares of common stock depending on whether Oncocyte elects to pay all or a portion of the restructured liabilities to certain of the selling shareholders in shares of its common stock. As such, Oncocyte will not issue all of the 9,436,465 shares of its common stock registered for resale in the registration statement. This presentation is not intended to constitute an indication or prediction of whether any of the future milestones will be achieved.

 

We will pay the expenses of registering the Resale Shares; however, we will not receive any of the proceeds from the sale of the Resale Shares.

 

The selling shareholders identified in this prospectus may offer the shares from time to time through public or private transactions at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The registration of the Resale Shares on behalf of the selling shareholders, however, does not necessarily mean that any of the selling shareholders will offer or sell their Resale Shares under this registration statement or at any time in the near future.

 

Investing in our common stock involves a high degree of risk. You should consider carefully the risk factors beginning on page 4 of this prospectus before purchasing any of the Resale Shares offered by this prospectus.

 

Our common stock is traded on The Nasdaq Global Market under the symbol “OCX.” The last reported sale price of our common stock on The Nasdaq Global Market on July 13, 2021, was $5.73 per share.

 

We are an “emerging growth company” under the federal securities laws and, as such, are subject to reduced public company reporting requirements.

 

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is July 29, 2021.

 

 

TABLE OF CONTENTS

 

	Page
SUMMARY	4
RISK FACTORS	4
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS	6
USE OF PROCEEDS	7
SELLING SHAREHOLDERS	7
DESCRIPTION OF CAPITAL STOCK	25
PLAN OF DISTRIBUTION	26
LEGAL MATTERS	28
EXPERTS	28
WHERE YOU CAN FIND MORE INFORMATION	28
INCORPORATION OF DOCUMENTS BY REFERENCE	28

 

You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the selling shareholders have authorized anyone to provide you with different information. Neither we nor the selling shareholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document. Since the respective dates of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed.

 

 

SUMMARY

 

The following summary highlights some information from this prospectus. It is not complete and does not contain all of the information that you should consider before making an investment decision. You should read this entire prospectus, including the “Risk Factors” section on page 4, the financial statements and related notes and the other more detailed information appearing elsewhere or incorporated by reference into this prospectus and any applicable prospectus supplement.

 

Overview

 

We are a molecular diagnostics company focused on developing and commercializing proprietary laboratory-developed tests, or LDTs, to serve unmet medical needs across the cancer care continuum. Our mission is to provide actionable information to physicians and patients at critical decision points to optimize diagnosis and treatment decisions, improve patient outcomes, and reduce overall cost of care. We have prioritized lung cancer as our first indication. Lung cancer remains the leading cause of cancer death in the United States, despite the availability of molecular testing and novel therapies to treat patients.

 

Our first commercial diagnostic test is a proprietary treatment stratification test called DetermaRx™ that identifies which patients with early stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. We are also developing multi-gene molecular, laboratory-developed diagnostic tests that we have branded as DetermaIO™. DetermaIO™ is a proprietary gene expression assay with promising data supporting its potential to help identify patients likely to respond to checkpoint inhibitor drugs. This new class of drugs modulates the immune response and shows activity in multiple solid tumor types including non-small cell lung cancer, and triple negative breast cancer. DetermaIO™ is presently available for research use but one of our goals is to complete development of that assay and to make it available for clinical use later this year. We also perform assay development and clinical testing services for pharmaceutical and biotechnology companies.

 

We recently added to our diagnostic test pipeline DetermaCNI™, a patented, blood-based test for immunotherapy monitoring. DetermaCNI was developed by Chronix Biomedical, Inc., which we acquired through a merger in April 2021. We plan to make the DetermaCNI monitor test available initially as a research tool.

 

Other tests in our development pipeline include DetermaTx™, a test that we are targeting for commercial launch later this year and that is intended to compliment DetermaIO™ by assessing the mutational status of a tumor to help identify the appropriate targeted therapy. We also plan to initiate the development of DetermaMx™ as a blood based test to monitor cancer patients for recurrence of their disease.

 

Corporate Information

 

We were incorporated in 2009 in the state of California. Our principal executive offices are located at 15 Cushing, Irvine, California 92618. Our telephone number is (949) 409-7600. Our website is www.oncocyte.com. Information contained on, or that can be accessed through, our website, is not, and shall not be deemed to be, incorporated in this prospectus supplement or considered a part thereof.

 

RISK FACTORS

 

Any investment in our common stock involves a high degree of risk. Before deciding whether to purchase our common stock, investors should carefully consider the risks described below together with the “Risk Factors” described in our most recent Annual Report on Form 10-K which are incorporated herein by reference, as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (“SEC”). Our business, financial condition, operating results and prospects are subject to the following material risks as well as those material risks incorporated by reference. Additional risks and uncertainties not presently foreseeable to us may also impair our business operations. If any of the following risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such case, the trading price of our common stock could decline, and our shareholders may lose all or part of their investment in the shares of our common stock.

 

 

We are an emerging growth company and a smaller reporting company under U.S. securities laws and may take advantage of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors.

 

We are an emerging growth company and smaller reporting company and may take advantage of certain exemptions from various reporting requirements that are otherwise applicable to public companies that are not emerging growth companies and/or smaller reporting companies including, but not limited to:

 

	●	not being required to comply with the auditor attestation requirements regarding internal controls under Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);
	●	reduced disclosure obligations regarding executive compensation in periodic reports and proxy statements;
	●	exemptions from the requirements of holding a non-binding shareholder advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved;
	●	exemption from the requirement to provide pay for performance disclosure; and
	●	exemption from the requirement to provide compensation ratio disclosure.

 

Moreover, we also are eligible under the Jumpstart Our Business Startups Act of 2012 for an exemption from compliance with any requirement that the Public Company Accounting Oversight Board may adopt regarding mandatory audit firm rotation or supplements to the auditor’s report providing additional information about the audit and the financial statements. We may take advantage of these reporting exemptions until we no longer are an emerging growth company. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (“Securities Act”); (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Even after we no longer qualify as an emerging growth company, we may still continue to qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from the disclosure requirements described above, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, and being subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statement.

 

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

A sale of a substantial number of shares of common stock by the selling shareholders may cause the price of our common stock to decline.

 

If our shareholders sell, or the market perceives that our shareholders intend to sell for various reasons, substantial amounts of our common stock in the public market, the price of our common stock may decline. Additionally, such conditions may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 

The price of our stock may rise and fall rapidly.

 

The market price of our common stock, like that of the shares of many biotechnology companies, may be highly volatile. The price of our common stock may rise or fall rapidly as a result of a number of factors, including:

 

	●	sales or potential sales of substantial amounts of our common stock;
	●	results of or delays in preclinical testing or clinical trials of our diagnostic test candidates;

 

 

	●	announcements about us or about our competitors, including clinical trial results, regulatory approvals, new diagnostic test introductions and commercial results;
	●	the cost of our development programs;
	●	the success of competitive diagnostic tests or technologies;
	●	litigation and other developments relating to our intellectual property or other proprietary rights or those of our competitors;
	●	conditions in the diagnostic, pharmaceutical or biotechnology industries;
	●	actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
	●	variations in our financial results or those of companies that are perceived to be similar to us, including the failure of our earnings to meet analysts’ expectations;
	●	general economic, industry and market conditions;
	●	changes in payer coverage and/or reimbursement; and
	●	impacts of the COVID-19 pandemic.

 

Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnological companies in particular, have been experiencing extreme price and volume fluctuations, which have affected the market price of the equity securities without regard to the operating performance of the issuing companies. Broad market fluctuations, as well as industry factors and general economic and political conditions, may adversely affect the market price of our common stock.

 

We will not receive any proceeds from the sale of the Resale Shares by the selling shareholders pursuant to this prospectus.

 

We are registering the Resale Shares that were, or may be, issued by us to the selling shareholders to permit the resale of these shares of common stock from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling shareholders of the Resale Shares.

 

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus and the documents incorporated by reference into this prospectus and any applicable prospectus supplement may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), about the Company and its subsidiaries. These forward-looking statements are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, and can be identified by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “could,” “should,” “projects,” “plans,” “goal,” “targets,” “potential,” “estimates,” “pro forma,” “seeks,” “intends,” or “anticipates” or the negative thereof or comparable terminology. Forward-looking statements include, among other things, statements about:

 

	●	the timing and potential achievement of future milestones;
	●	the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers;
	●	our plans to pursue research and development of diagnostic test candidates;
	●	the potential commercialization of our diagnostic tests currently in development;
	●	the timing and success of future clinical trials and the period during which the results of the clinical trials will become available;
	●	the potential receipt of revenue from future sales of our diagnostic tests or tests in development;
	●	our assumptions regarding obtaining reimbursement and reimbursement rates;
	●	our estimates regarding future orders of tests and our ability to perform a projected number of tests;
	●	our estimates and assumptions around patient populations, market size and price points for reimbursement for our diagnostic tests;
	●	our estimates regarding future revenues and operating expenses, and future capital requirements;
	●	our intellectual property position;

 

 

	●	the impact of the COVID-19 pandemic on our operations and demand for our diagnostic tests and pharma services;
	●	our ability to expand our operations in the United States and abroad;
	●	the impact of government laws and regulations; and
	●	our competitive position.

 

We caution our shareholders and other readers not to place undue reliance on such statements.

 

You should read this prospectus and the documents incorporated by reference completely and with the understanding that our actual future results may be materially different from what we currently expect. Our business and operations are and will be subject to a variety of risks, uncertainties and other factors. Consequently, actual results may materially differ from those contained in any forward-looking statements. Such risks, uncertainties and other factors that could cause actual results to differ from those projected include, but are not limited to, the risk factors set forth herein under the title “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2020, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC, and elsewhere in the documents incorporated by reference into this prospectus and any applicable prospectus supplement.

 

You should assume that the information appearing in this prospectus and any document incorporated herein by reference is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which the statement is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All written or oral forward-looking statements attributable to us or any person acting on our behalf made after the date of this prospectus and any applicable prospectus supplement are expressly qualified in their entirety by the risk factors and cautionary statements contained in and incorporated by reference into this prospectus and any applicable prospectus supplement. Unless required by law, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this prospectus and any applicable prospectus supplement or to reflect the occurrence of unanticipated events.

 

USE OF PROCEEDS

 

The net proceeds from any disposition of the Resale Shares covered hereby will be received by the selling shareholders. We will not receive any of the proceeds from any such Resale Shares offered by this prospectus.

 

SELLING SHAREHOLDERS

 

This prospectus relates to the offering of up to 9,436,465 shares of our common stock issued or to be issued to the selling shareholders named herein in connection with our acquisitions of Razor Genomics, Inc. (“Razor”) and Chronix Biomedical, Inc. (“Chronix”) in the first half of 2021.

 

Resale Shares Issued in Connection with our Acquisition of Razor

 

We issued 982,318 of the Resale Shares (“Razor Resale Shares”) to certain selling shareholders on or about February 24, 2021 pursuant to a Subscription and Stock Purchase Agreement, dated September 4, 2019 (“Razor Purchase Agreement”), by and among Oncocyte, Encore Clinical, Inc. (“Encore”), and Razor, and pursuant to certain Minority Holder Stock Purchase Agreements of like tenor with the shareholders of Razor other than Encore (“Minority Purchase Agreements”). As a result of the acquisition, Razor is now a wholly-owned subsidiary of Oncocyte. The Razor Resale Shares were issued to the former shareholders of Razor without registration under the Securities Act in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

 

 

Resale Shares Issued and Issuable in Connection with our Acquisition of Chronix

 

In connection with our acquisition of Chronix pursuant to the Amended and Restated Agreement and Plan of Merger (“Merger Agreement”), dated as of April 15, 2021 (“Closing Date”), by and among the Company, CNI Monitor Sub, Inc., Chronix, the shareholders party thereto and David MacKenzie as the equityholder representative, we delivered 647,911 shares of our common stock (“Chronix Closing Shares”) as of the Closing Date to certain selling shareholders pursuant to the Merger Agreement. We may also issue up to 7,213,089 Earnout Shares that may become issuable to certain selling shareholders as earnout payments pursuant to the terms of the Merger Agreement contingent upon the achievement of milestones specified in the Merger Agreement and/or up to 593,147 Restructured Shares that may become issuable to certain named selling shareholders as payments for restructured liabilities incurred by Chronix pursuant to the terms of agreements between us and such selling shareholders contingent upon whether we elect to pay all of a portion of the payments to the selling shareholder in shares of our common stock. However, pursuant to the Merger Agreement, we cannot issue all 7,213,089 Earnout Shares and all 593,147 Restructured Shares because the maximum number of our shares of common stock issuable under the Merger Agreement is 7,861,000 which is inclusive of the Chronix Closing Shares we have already issued. Nonetheless, we have included the maximum number of Earnout Shares and Restructured Shares in the total Resale Shares registered for resale pursuant to this prospectus because we have not yet determined the actual number of Earnout Shares and/or Restructured Shares we will issue in lieu of cash if the milestones set forth in the Merger Agreement are achieved. The shares issued pursuant to the Merger Agreement were or will be issued without registration under the Securities Act in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder to persons reasonably believed to be “accredited investors” as defined in Rule 501 under the Securities Act, or pursuant to Regulation S under the Securities Act to non-U.S. persons located outside the United States.

 

The Earnout Shares have not been earned and have not been issued as of the date of this prospectus. The Merger Agreement provides for earnout payments of up to $14 million upon the achievement of certain milestones set forth therein, subject to offset for certain liabilities of Chronix. For purposes of this prospectus, we have calculated the number of Earnout Shares based on the assumption that the maximum number of shares of our common stock that remains available for issuance pursuant to the Merger Agreement may be issued as earnout payments. The actual number of Earnout Shares issued to the selling shareholders as earnout payments, if any, could be materially less than 7,213,089 shares of common stock depending on (a) whether and to what extent the applicable future milestones are achieved, (b) the amount of offsets for certain liabilities of Chronix, (c) whether we elect to pay all or a portion of the earnout payments to the selling shareholders in shares of our common stock, and (d) the actual closing price of our common stock on the trading day immediately preceding the date upon which we publicly announce that a milestone has been satisfied. Similarly, the Restructured Shares have not been issued as of the date of this prospectus, and the actual number of Restructured Shares issued to the selling shareholders as payments for restructured liabilities, if any, could be materially less than 593,147 shares of common stock depending on whether we elect to pay all or a portion of the restructured liabilities to certain of the selling shareholders in shares of our common stock. As such, we will not issue all of the 9,436,465 shares of our common stock registered for resale pursuant to this prospectus. This presentation is not intended to constitute an indication or prediction of whether any of the future milestones will be achieved or the future market price of our common stock.

 

Certain Information Concerning the Selling Shareholders

 

The following table sets forth, based on information provided to us by or on behalf of the selling shareholders or known to us, the names of the selling shareholders, the nature of any position, office or other material relationship, if any, which the selling shareholders have had, within the past three years, with us or with any of our predecessors or affiliates, and the number of shares of our common stock beneficially owned by the selling shareholders before and after this offering. The number of shares owned are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares of common stock as to which a person has sole or shared voting power or investment power and any shares of common stock that the person has the right to acquire within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement. Except as otherwise set forth herein, none of the selling shareholders are a broker-dealer or an affiliate of a broker-dealer.

 

 

For each selling shareholder listed on the table, we have calculated the maximum number of Resale Shares that could potentially become saleable by such selling shareholder pursuant to this prospectus if such selling shareholder were to receive the maximum number of Earnout Shares and Restructured Shares issuable to such selling shareholder under the Merger Agreement. When those individual amounts are aggregated, it suggests that the total number of Resale Shares saleable pursuant to this prospectus is 9,436,465. However, the total number of Resale Shares saleable pursuant to this prospectus will not exceed an aggregate of 8,843,318 shares because if any of the 593,147 Restructured Shares are issued to some of the selling shareholders then the same number of Earnout Shares will be deducted from other selling shareholders, who may receive cash in lieu of shares, because the maximum number of our shares we can issue under the Merger Agreement cannot exceed 7,861,000 shares. We have already issued the Chronix Closing Shares under the Merger Agreement, and we can only issue up to 7,213,089 additional shares as Earnout Shares and/or Restructured Shares under the Merger Agreement.

 

For purposes of calculating the number of Resale Shares saleable pursuant to this prospectus, we have assumed that all of the Resale Shares issued or issuable to the selling shareholders covered by this prospectus are sold and that the selling shareholders acquire no additional shares of common stock before the completion of this offering. However, because the selling shareholders can offer all, some, or none of their Resale Shares, no definitive estimate can be given as to the number of Resale Shares that the selling shareholders will ultimately offer or sell under this prospectus or the number of Resale Shares that will be held by the selling shareholders upon termination of this offering.

 

		Beneficial Ownership of Common Stock Prior to the Offering								Common Stock Saleable Pursuant					Beneficial Ownership of Common Stock After the Offering (1)
		Number of				Percent of				to This					Number of				Percent of
Name of Selling Shareholder1		Shares				Class (2)				Prospectus					Shares				Class (2)
A. MIGUEZ & C. PARADA			0				0	%			13,086		(3)			0				0	%
ADAMS FAMILY TRUST (4)			0				0	%			4,139		(5)			0				0	%
ADV MED HOLDING (6)			4,773				*				146,487		(7)			0				0	%
ALEJANDRO PODGAEZKY			0				0	%			10,067		(8)			0				0	%
ALEKSANDER WITOLD WIERCINSKI			2,281				*				98,201		(9)			0				0	%
ALLEN FINCH			477				*				4,582		(10)			0				0	%
AMY S. ULLMAN			7,777				*				49,166		(11)			0				0	%
ANDREW BENSON			1,166				*				11,197		(12)			0				0	%
ANISUZ CHOWDHURY			0				0	%			13,086		(13)			0				0	%
ANNA METAXATOU			0				0	%			10,067		(14)			0				0	%
ANTONIO FERREIRO			0				0	%			18,120		(15)			0				0	%
ARTHUR RODERICK MACKENZIE			0				0	%			17,916		(16)			0				0	%

 

 

ASPAROUH ALEXANDROV			0				0	%			6,040		(17)			0				0	%
BEATRIZ ENCINAS			0				0	%			10,067		(18)			0				0	%
BEAUFORT NOMINEES LTD (19)			0				0	%			25,167		(20)			0				0	%
BEHEKO CORP. LTD (21)			4,773				*				394,036		(22)			0				0	%
BENALMEDA FOUNDATION (23)			1,194				*				11,464		(24)			0				0	%
BOUSTEAD COMPANY LIMITED (25)			61,805				*				61,805		(26)			0				0	%
BOUSTEAD SECURITIES LLC (27)			131,630				*				193,380		(28)			0				0	%
BYZANTINE PARTNERS (29)			10,249				*				261,520		(30)			0				0	%
CARLOS JUNCO & ROSA MARIA RENEDO			0				0	%			8,053		(31)			0				0	%
CHARLES SPENCER-SMITH			0				0	%			10,067		(32)			0				0	%
CHARLOTTE MARIE KEATING, AS ADMINISTRATOR OF VICTOR MORRISH’S ESTATE			18,643				*				178,958		(33)			0				0	%
CLARA BASILE LIVING TRUST DTD 5/24/06 (34)			2,386				*				43,611		(35)			0				0	%
CONSTANCE WOLF LIVING TRUST (36)			1,193				*				11,455		(37)			0				0	%
CORIL HOLDINGS LTD (38)			0				0	%			42,025		(39)			0				0	%
CRICKLADE INVESTMENTS LTD. (40)			4,833				*				46,394		(41)			0				0	%
DANAE PAPASTAMATI & ELLI KINATOU			0				0	%			5,033		(42)			0				0	%
DANIEL B. DEBRA			0				0	%			21,252		(43)			0				0	%
DAVID R. MACKENZIE			82,669	(44)			*				17,916		(45)			82,669				*
DEBORAH CAROL COOPER			0				0	%			2,069		(46)			0				0	%
DISRUPTIVE VENTURES INC. (47)			0				0	%			17,916		(48)			0				0	%
DONALD L. MACKENZIE			0				0	%			17,916		(49)			0				0	%
DOROTA LANGE-SOCHA			4,897				*				47,012		(50)			0				0	%
DR. GERD BOHMER			1,450				*				13,922		(51)			0				0	%
DR. HELMUT WAGNER			13,266				*				379,015		(52)			0				0	%
DR. JAMAL Y.A. ALTARKAIT			0				0	%			29,632		(53)			0				0	%

 

 

DR. MED CLAUDIA STOLTE			1,450				*				13,922		(54)			0				0	%
DR. RALF GLAUBITZ (55)			13,297				*				127,647		(56)			0				0	%
ELLEN ULLMAN			4,365				*				49,859		(57)			0				0	%
EMERSON STREET VENTURES (58)			51,806				*				194,506		(59)			0				0	%
EMILIO MARTINEZ			0				0	%			7,550		(60)			0				0	%
ENERCHIEVE VENTURES LIMITED (61)			27,213				*				261,229		(62)			0				0	%
FIRST NATIONAL VENTURE CAPITAL (63)			0				0	%			20,951		(64)			0				0	%
GABINO LALINDE			1,775				*				32,143		(65)			0				0	%
GARETH PICKERING			2,685				*				76,108		(66)			0				0	%
GARY PALMER			2,386				*				22,910		(67)			0				0	%
GONZALO PODGAEZKY			0				0	%			10,067		(68)			0				0	%
HARRIS BERENHOLZ			0				0	%			2,069		(69)			0				0	%
HARRY R. WOLF			2,152	(70)			*				32,760		(71)			959				*
HILLCREST PHARMACIES LTD (72)			0				0	%			37,750		(73)			0				0	%
IGNACIO RUZ & REYES VELAZQUEZ			0				0	%			5,033		(74)			0				0	%
INNOCREATIVE CAPITAL LLC (75)			0				0	%			84,050		(76)			0				0	%
ITZIAR FERNANDEZ DE MENDIOLA			355				*				8,442		(77)			0				0	%
JACEK KWASIEWSKI			1,194				*				11,464		(78)			0				0	%
JAMES K. ROBERTSON, JR.			0				0	%			75,072		(79)			0				0	%
JAVIER MIGUELEZ & DOLORES GONZALEZ			976				*				17,427		(80)			0				0	%
JOAN DYCK			1,193				*				11,455		(81)			0				0	%
JOHN CAMPBELL ROBERTSON			0				0	%			15,100		(82)			0				0	%
JONATHAN FINNING			233				*				2,239		(83)			0				0	%
JOSE LUIS LACRUZ & MARINA SIFUENTES DE LACRUZ			0				0	%			15,100		(84)			0				0	%
JOSE MANUEL RUZ & MARIA AFRICA SAMPALO			0				0	%			5,033		(85)			0				0	%

 

 

JUAN LAGO			1,710				*				16,423		(86)			0				0	%
JUAN PINUAGA			0				0	%			3,020		(87)			0				0	%
JURGEN FRERIKS			1,418				*				13,616		(88)			0				0	%
KAREN KNUDSON TRUST DTD 12/28/1999 (89)			2,386				*				43,605		(90)			0				0	%
KATINA TEGOPOULOU & LEONIDAS TEGOPOULOS			710				*				11,851		(91)			0				0	%
LEONIDAS MAVROUDIS & VASILEOS MAVROUDIS			0				0	%			3,020		(92)			0				0	%
LIMITLESS EARTH PLC (93)			0				0	%			251,665		(94)			0				0	%
LIQUID BIOPSY CENTER GMBH, GOTTINGEN (95)			10,613				*				101,880		(96)			0				0	%
LONGTAIL COVE LTD. (97)			4,833				*				46,394		(98)			0				0	%
LP INVISO GMBH (99)			15,552				*				149,286		(100)			0				0	%
M. DWYER & CATHERINE HARDIMAN			2,386				*				73,243		(101)			0				0	%
MAITANE MENDIOLA			0				0	%			10,067		(102)			0				0	%
MANOLITA HERRAEZ			0				0	%			3,020		(103)			0				0	%
MARIA LUISA GAVINO			0				0	%			8,053		(104)			0				0	%
MARK STEPHENSON			0				0	%			7,550		(105)			0				0	%
MARY CORKE			0				0	%			17,916		(106)			0				0	%
MARZIA CARISSIMO			0				0	%			8,053		(107)			0				0	%
MEI CHU			4,773				*				45,821		(108)			0				0	%
MICHAEL A. FREEMAN REVOCABLE TRUST U/A DTD 12/02/2004 (109)			477				*				25,276		(110)			0				0	%
MICHAL BARLOWSKI			1,193				*				11,455		(111)			0				0	%
MICHAEL H. DAVIES			0				0	%			5,033		(112)			0				0	%
MIGUEL ANGEL ACEBES & FRANCISCA MORENO			1,331				*				22,849		(113)			0				0	%
SINGER 1995 FAMILY TRUST (114)			4,773				*				301,469		(115)			0				0	%
MORSAL, LLC (116)			959				*				9,210		(117)			0				0	%

 

 

MURATTI TRADING S.A. (118)			0				0	%			5,033		(119)			0				0	%
NICOLAS SANCHEZ			0				0	%			5,033		(120)			0				0	%
NIGEL OXBROW & BINDY PEASE			0				0	%			25,167		(121)			0				0	%
NORMA MACKENZIE			0				0	%			84,278		(122)			0				0	%
OBERMAN/GARDNER REVOCABLE TRUST DTD 10/09/2021 (123)			0				0	%			10,347		(124)			0				0	%
PAUL FREIMAN (125)			1,555				*				8,759		(126)			0				0	%
PAZ GOMEZ-RODULFO			0				0	%			2,517		(127)			0				0	%
PEDRO LAGO			1,322				*				12,691		(128)			0				0	%
PETER AEGIDIUS			710				*				21,917		(129)			0				0	%
PETER C. MORSE			4,773				*				46,181		(130)			0				0	%
PETER L. STEIN REVOCABLE TRUST DATED OCTOBER 22, 2018 (131)			1,477				*				25,919		(132)			0				0	%
PETER MEYER AND KRISTEN YOUNT			477				*				14,711		(133)			0				0	%
PIERS N. PLOWMAN			0				0	%			877,244		(134)			0				0	%
PIOTR GALAZKA			1,396				*				13,403		(135)			0				0	%
PROF. DR. BERND EIBEN			7,978				*				76,588		(136)			0				0	%
PROF. DR. EKKEHARD SCHUTZ (137)			5,319				*				234,780		(138)			0				0	%
RAFAEL SANCHEZ-LOZANO & ANA ISABEL VELASCO			0				0	%			20,133		(139)			0				0	%
RAYMOND JAMES & ASSOC. INC. CSDN FBO WILLIAM M MITCHELL RIRA			1,193				*				11,455		(140)			0				0	%
RENEE B. PONDER/NONA STUCKELMAN			0				0	%			10,347		(141)			0				0	%
RITESH RAMESH SANGHAVI			10,296				*				10,296		(142)			0				0	%
ROBERT CINNAMON			3,888				*				37,326		(143)			0				0	%
ROBERT LEPPO (144)			21,137	(145)			*				10,888		(146)			10,249				*
ROCHFORD YOUNG			0				0	%			20,694		(147)			0				0	%
ROGER MOSS			4,773				*				45,821		(148)			0				0	%

 

 

ROMIL PATEL			0				0	%			15,150		(149)			0				0	%
ROY DYKES			0				0	%			14,093		(150)			0				0	%
RUI MIGUEL LUCAS MENDES			0				0	%			12,583		(151)			0				0	%
S. JANE MORRILL			0				0	%			17,916		(152)			0				0	%
SAH DISTRIBUTION LTD (153)			458				*				4,403		(154)			0				0	%
SANDRA SLANKAMENAC			0				0	%			12,080		(155)			0				0	%
SIMON MACNAB			3,551				*				34,087		(156)			0				0	%
SIMON SKELDING			0				0	%			37,750		(157)			0				0	%
SOFIA BIRMAN			2,388				*				22,929		(158)			0				0	%
SOKRATIS METAXATOS			0				0	%			2,517		(159)			0				0	%
SVEN KOSTER			1,347				*				12,933		(160)			0				0	%
TERESA TACHOVSKY TRUST DTD 12/28/1999 (161)			2,386				*				43,605		(162)			0				0	%
TERRY WALKER			5,011	(163)			*				4,911		(164)			100				*
THE ALAN F. MORCOS TRUST DATED 5/14/96 (165)			0				0	%			20,694		(166)			0				0	%
THE HAROLD S. AND VERA STEIN REVOCABLE TRUST DTD 5/17/1995 (167)			238				*				23,628		(168)			0				0	%
THOMAS P. CALLAHAN			0				0	%			20,695		(169)			0				0	%
TIMOTHY MH DODD			935	(170)			*				4,582		(171)			458				*
VICENTE GARCIA			0				0	%			10,067		(172)			0				0	%
VICTORIA BIOVENTURES LTD. (173)			0				0	%			100,666		(174)			0				0	%
TREVIA INVEST AG (175)			0				0	%			125,833		(176)			0				0	%
TREVIA INVEST LIMITED (177)			7,637				*				73,314		(178)			0				0	%
VORACIOUS VENTURES, INC. (179)			82,669				*				484,599		(180)			0				0	%
WHITE MOVECVA LIMITED (181)			4,773				*				171,654		(182)			0				0	%
WIESLAWA MAJOREK			2,360				*				22,656		(183)			0				0	%
WLODZIMIERZ GAJEWSKI			2,362				*				22,681		(184)			0				0	%

 

 

WOLF FOUNDATION (185)			954				*				9,164		(186)			0				0	%
XINYUE GUO			2,219				*				21,304		(187)			0				0	%
YALDA JAMSHIDI			0				0	%			2,970		(188)			0				0	%
YOKE MIN FAN			1,710				*				75,956		(189)			0				0	%
BIAO HE			24,622				*				24,622		(190)